C 338 | CAS#15539-44-3

MedKoo Cat#: 534985 | Name: C 338

Description:

WARNING: This product is for research use only, not for human or veterinary use.

C 338 is a bioactive chemical.

Chemical Structure

C 338

CAS#15539-44-3

Theoretical Analysis

MedKoo Cat#: 534985

Name: C 338

CAS#: 15539-44-3

Chemical Formula: C17H20Cl2N4O2

Exact Mass: 382.0963

Molecular Weight: 383.27

Elemental Analysis: C, 53.27; H, 5.26; Cl, 18.50; N, 14.62; O, 8.35

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

C 338; C-338; C338

IUPAC/Chemical Name

1,2-Ethanediamine, N,N-dimethyl-N'-(2-nitro-9-acridinyl)-, dihydrochloride

InChi Key

VVYQKKKUMWXTCG-UHFFFAOYSA-N

InChi Code

InChI=1S/C17H18N4O2.2ClH/c1-20(2)10-9-18-17-13-5-3-4-6-15(13)19-16-8-7-12(21(22)23)11-14(16)17;;/h3-8,11H,9-10H2,1-2H3,(H,18,19);2*1H

SMILES Code

O=[N+](C1=CC2=C(NCCN(C)C)C3=CC=CC=C3N=C2C=C1)[O-].[H]Cl.[H]Cl

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 383.27 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Vivacqua A, Sebastiani A, Miglietta AM, Rigiracciolo DC, Cirillo F, Galli GR, Talia M, Santolla MF, Lappano R, Giordano F, Panno ML, Maggiolini M. miR-338-3p Is Regulated by Estrogens through GPER in Breast Cancer Cells and Cancer- Associated Fibroblasts (CAFs). Cells. 2018 Nov 9;7(11):203. doi: 10.3390/cells7110203. PMID: 30423928; PMCID: PMC6262471. 2: Liang Y, Xu X, Wang T, Li Y, You W, Fu J, Liu Y, Jin S, Ji Q, Zhao W, Song Q, Li L, Hong T, Huang J, Lyu Z, Ye Q. The EGFR/miR-338-3p/EYA2 axis controls breast tumor growth and lung metastasis. Cell Death Dis. 2017 Jul 13;8(7):e2928. doi: 10.1038/cddis.2017.325. PMID: 28703807; PMCID: PMC5550870. 3: Niu Q, Liu Z, Gao J, Wang Q. MiR-338-3p Enhances Ovarian Cancer Cell Sensitivity to Cisplatin by Downregulating WNT2B. Yonsei Med J. 2019 Dec;60(12):1146-1156. doi: 10.3349/ymj.2019.60.12.1146. PMID: 31769245; PMCID: PMC6881712. 4: Zhang R, Shi H, Ren F, Feng W, Cao Y, Li G, Liu Z, Ji P, Zhang M. MicroRNA-338-3p suppresses ovarian cancer cells growth and metastasis: implication of Wnt/catenin beta and MEK/ERK signaling pathways. J Exp Clin Cancer Res. 2019 Dec 16;38(1):494. doi: 10.1186/s13046-019-1494-3. PMID: 31842953; PMCID: PMC6916056. 5: Qian Q, Zhang J, He FP, Bao WX, Zheng TT, Zhou DM, Pan HY, Zhang H, Zhang XQ, He X, Sun BG, Luo BY, Chen C, Peng GP. Down-regulated expression of microRNA-338-5p contributes to neuropathology in Alzheimer's disease. FASEB J. 2019 Mar;33(3):4404-4417. doi: 10.1096/fj.201801846R. Epub 2018 Dec 21. PMID: 30576233; PMCID: PMC6404576. 6: Lu R, Yang Z, Xu G, Yu S. miR-338 modulates proliferation and autophagy by PI3K/AKT/mTOR signaling pathway in cervical cancer. Biomed Pharmacother. 2018 Sep;105:633-644. doi: 10.1016/j.biopha.2018.06.024. Epub 2018 Jun 10. PMID: 29898430. 7: Wang LG, Huangfu XQ, Tao B, Zhong GJ, Le ZD. Serum tenascin-C predicts severity and outcome of acute intracerebral hemorrhage. Clin Chim Acta. 2018 Jun;481:69-74. doi: 10.1016/j.cca.2018.02.033. Epub 2018 Feb 27. PMID: 29499198. 8: Long J, Luo J, Yin X. MiR-338-5p promotes the growth and metastasis of malignant melanoma cells via targeting CD82. Biomed Pharmacother. 2018 Jun;102:1195-1202. doi: 10.1016/j.biopha.2018.03.075. Epub 2018 Apr 10. PMID: 29710538. 9: Song B, Lin HX, Dong LL, Ma JJ, Jiang ZG. MicroRNA-338 inhibits proliferation, migration, and invasion of gastric cancer cells by the Wnt/β-catenin signaling pathway. Eur Rev Med Pharmacol Sci. 2018 Mar;22(5):1290-1296. doi: 10.26355/eurrev_201803_14470. PMID: 29565486. 10: Menon BR, Menon N, Fisher K, Rigby SE, Leys D, Scrutton NS. Glutamate 338 is an electrostatic facilitator of C-Co bond breakage in a dynamic/electrostatic model of catalysis by ornithine aminomutase. FEBS J. 2015 Apr;282(7):1242-55. doi: 10.1111/febs.13215. Epub 2015 Feb 12. PMID: 25627283; PMCID: PMC4413051. 11: Liu J, Cao L, Feng Y, Li Y, Li T. MiR-338-3p inhibits TNF-α-induced lipogenesis in human sebocytes. Biotechnol Lett. 2017 Sep;39(9):1343-1349. doi: 10.1007/s10529-017-2369-3. Epub 2017 Jun 9. PMID: 28597147. 12: Cao R, Shao J, Hu Y, Wang L, Li Z, Sun G, Gao X. microRNA-338-3p inhibits proliferation, migration, invasion, and EMT in osteosarcoma cells by targeting activator of 90 kDa heat shock protein ATPase homolog 1. Cancer Cell Int. 2018 Apr 2;18:49. doi: 10.1186/s12935-018-0551-x. PMID: 29618948; PMCID: PMC5879792. 13: Sun F, Yu M, Yu J, Liu Z, Zhou X, Liu Y, Ge X, Gao H, Li M, Jiang X, Liu S, Chen X, Guan W. miR-338-3p functions as a tumor suppressor in gastric cancer by targeting PTP1B. Cell Death Dis. 2018 May 1;9(5):522. doi: 10.1038/s41419-018-0611-0. PMID: 29743567; PMCID: PMC5943282. 14: Zheng J, Luo J, Zeng H, Guo L, Shao G. 125I suppressed the Warburg effect viaregulating miR-338/PFKL axis in hepatocellular carcinoma. Biomed Pharmacother. 2019 Nov;119:109402. doi: 10.1016/j.biopha.2019.109402. Epub 2019 Sep 9. PMID: 31514072. 15: Zhuang Y, Dai J, Wang Y, Zhang H, Li X, Wang C, Cao M, Liu Y, Ding J, Cai H, Zhang D, Wang Y. MiR-338* targeting smoothened to inhibit pulmonary fibrosis by epithelial-mesenchymal transition. Am J Transl Res. 2016 Jul 15;8(7):3206-13. PMID: 27508042; PMCID: PMC4969458. 16: Dou L, Wang S, Sun L, Huang X, Zhang Y, Shen T, Guo J, Man Y, Tang W, Li J. Mir-338-3p Mediates Tnf-A-Induced Hepatic Insulin Resistance by Targeting PP4r1 to Regulate PP4 Expression. Cell Physiol Biochem. 2017;41(6):2419-2431. doi: 10.1159/000475912. Epub 2017 May 3. PMID: 28467989. 17: Kos A, de Mooij-Malsen AJ, van Bokhoven H, Kaplan BB, Martens GJ, Kolk SM, Aschrafi A. MicroRNA-338 modulates cortical neuronal placement and polarity. RNA Biol. 2017 Jul 3;14(7):905-913. doi: 10.1080/15476286.2017.1325067. Epub 2017 May 11. PMID: 28494198; PMCID: PMC5546544. 18: Teng L, Meng R. Long Non-Coding RNA MALAT1 Promotes Acute Cerebral Infarction Through miRNAs-Mediated hs-CRP Regulation. J Mol Neurosci. 2019 Nov;69(3):494-504. doi: 10.1007/s12031-019-01384-y. Epub 2019 Jul 24. PMID: 31342266. 19: Hugon J, Mouton-Liger F, Cognat E, Dumurgier J, Paquet C. Blood-Based Kinase Assessments in Alzheimer's Disease. Front Aging Neurosci. 2018 Nov 14;10:338. doi: 10.3389/fnagi.2018.00338. PMID: 30487744; PMCID: PMC6246745. 20: Stasiak M, Tymoniuk B, Stasiak B, Lewiński A. The Risk of Recurrence of Subacute Thyroiditis Is HLA-Dependent. Int J Mol Sci. 2019 Mar 3;20(5):1089. doi: 10.3390/ijms20051089. PMID: 30832406; PMCID: PMC6429176.